Abstract
We have investigated the effects of short-term neoadjuvant and long-term androgen deprivation therapies (ADTs) on β-microseminoprotein (MSMB) and cysteine-rich secretory protein-3 (CRISP3) expression in prostate cancer patients. We also studied if MSMB expression was related to genotype and epigenetic silencing. Using an Affymetrix cDNA microarray analysis, we investigated the expression of MSMB, CRISP3, androgen receptor (AR), KLK3 and Enhancer of Zeste Homologue-2 (EZH2) in tissue from prostate cancer patients receiving (n=17) or not receiving (n=23) ADT before radical prostatectomy. MSMB, CRISP3 and AR were studied in tissue from the same patients undergoing TURP before and during ADT (n=16). MSMB genotyping of these patients was performed by TaqMan PCR. MSMB and KLK3 expression levels decreased during ADT. Expression levels of AR and CRISP3 were not affected by short-term ADT but were high in castration-resistant prostate cancer (CRPC) and metastases. Levels of EZH2 were also high in metastases, where MSMB was low. Genotyping of the MSMB rs10993994 polymorphism showed that the TT genotype conveys poor MSMB expression. MSMB expression is influenced by androgens, but also by genotype and epigenetic silencing. AR and CRISP3 expression are not influenced by short-term ADT, and high levels were found in CRPC and metastases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
Lilja H, Abrahamsson P-A . Three predominant proteins secreted by the human prostate gland. Prostate 1988; 12: 29–38.
Abrahamsson PA, Andersson C, Bjork T, Fernlund P, Lilja H, Murne A et al. Radioimmunoassay of beta-microseminoprotein, a prostatic-secreted protein present in sera of both men and women. Clin Chem 1989; 35: 1497–1503.
Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE . The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 2009; 70: 333–340.
Tsurusaki T, Koji T, Sakai H, Kanetake H, Nakane PK, Saito Y . Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer. Prostate 1998; 35: 109–116.
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624–629.
Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M . The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007; 26: 4590–4595.
Girvan AR, Chang P, van Huizen I, Moussa M, Xuan JW, Stitt L et al. Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer. Urology 2005; 65: 719–723.
Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW et al. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 2007; 13: 4130–4138.
Sakai H, Tsurusaki T, Kanda S, Koji T, Xuan JW, Saito Y . Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. Prostate 1999; 38: 278–284.
Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310–315.
Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316–321.
Chang BL, Cramer SD, Wiklund F, Isaacs SD, Stevens VL, Sun J et al. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 2009; 18: 1368–1375.
Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N et al. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA 2009; 106: 7933–7938.
Kote-Jarai Z, Leongamornlert D, Tymrakiewicz M, Field H, Guy M, Al Olama AA et al. Mutation analysis of the MSMB gene in familial prostate cancer. Br J Cancer 2009; 102: 414–418.
Wu D, Guo Y, Chambers AF, Izawa JI, Chin JL, Xuan JW . Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. J Cell Biochem 1999; 76: 71–83.
Reeves JR, Xuan JW, Arfanis K, Morin C, Garde SV, Ruiz MT et al. Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem J 2005; 385 (Part 1): 105–114.
Reeves JR, Dulude H, Panchal C, Daigneault L, Ramnani DM . Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res 2006; 12 (20 Part 1): 6018–6022.
Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 2006; 175: 1291–1297.
Udby L, Lundwall A, Johnsen AH, Fernlund P, Valtonen-Andre C, Blom AM et al. beta-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun 2005; 333: 555–561.
Asmann YW, Kosari F, Wang K, Cheville JC, Vasmatzis G . Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res 2002; 62: 3308–3314.
Udby L, Bjartell A, Malm J, Egesten A, Lundwall A, Cowland JB et al. Characterization and localization of cysteine-rich secretory protein 3 (CRISP-3) in the human male reproductive tract. J Androl 2005; 26: 333–342.
Kosari F, Asmann YW, Cheville JC, Vasmatzis G . Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 1419–1426.
Bjartell A, Johansson R, Bjork T, Gadaleanu V, Lundwall A, Lilja H et al. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate 2006; 66: 591–603.
Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164: 217–227.
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33–39.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787–790.
Imasato Y, Xuan JW, Sakai H, Izawa JI, Saito Y, Chin JL et al. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer. J Urol 2000; 164: 1819–1824.
Acknowledgements
We thank Jeff Holzbeierlein and the American Society for Investigative Pathology for permission to reprint the microarray data on AR expression; Elise Nilsson for excellent technical skills in the field of immunohistochemistry; Lene Udby for providing the CRISP3 antibody and Per Fernlund for the MSMB antibody.
Supporting grants: European Union 6th Framework (P-Mark) (Grant number LSHC-CT-2004-503011), Swedish Cancer Society, Swedish Research Council (Medicine), Cancer and Research Foundation at University Hospital Malmö, Gunnar Nilsson Cancer Foundation and the Crafoord Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interests.
Rights and permissions
About this article
Cite this article
Dahlman, A., Edsjö, A., Halldén, C. et al. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. Prostate Cancer Prostatic Dis 13, 369–375 (2010). https://doi.org/10.1038/pcan.2010.25
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2010.25
Keywords
This article is cited by
-
miR-32 promotes MYC-driven prostate cancer
Oncogenesis (2022)
-
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets
Nature Communications (2022)
-
Cysteine-rich secretory protein 3 plays a role in prostate cancer cell invasion and affects expression of PSA and ANXA1
Molecular and Cellular Biochemistry (2016)
-
Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence
Modern Pathology (2013)
-
Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis
Modern Pathology (2011)